Decoding AbbVie's Options Activity: What's the Big Picture?

Benzinga15:01 ET

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Benzinga12:39 ET

How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks

Seeking Alpha12:37 ET

Novo-Nordisk A/S recorded its largest monthly decline in over 20 years. The long-term outlook remains Bullish, but the short-term rebound is lackluster.

①The Danish weight-loss drug giant Novo-Nordisk A/S has recorded its worst monthly performance in over twenty years; although Analysts remain Bullish on the stock's long-term prospects, there is a lack of catalysts expected to stimulate a rebound in the stock price in the short term. ② Since hitting an all-time high last June, the share price of Novo-Nordisk A/S has faced multiple setbacks.

cls.cn12:09 ET

Merck Highlights Phase 3 ZENITH Trial Evaluating WINREVAIR; Says Trial Stopped Early Due To 'Overwhelming Efficacy Demonstrated in the Primary Endpoint'

BenzingaMar 31 10:08 ET

Eli Lilly and Co's drug has achieved positive clinical results and is expected to reduce the risk of hereditary cardiovascular diseases.

①Eli Lilly and Co announced that its small interfering RNA therapy, lepodisiran, achieved positive results in Phase II clinical research, with the highest dose reducing participants' lipoprotein a levels by an average of 93.9% over 60 to 180 days; ②Elevated lipoprotein a levels are a common risk factor for heart disease and are difficult to lower even with lifestyle changes, affecting about one-fifth of the global population.

cls.cnMar 31 09:09 ET